千红制药: 详式权益变动报告书

Core Viewpoint - The report details the equity change of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd., highlighting the increase in shareholding by the information disclosure obligor, Wang Ke, through block trading, reflecting confidence in the company's long-term investment value and future development prospects [1][6]. Group 1: Equity Change Details - Wang Ke increased his shareholding in Qianhong Pharmaceutical by acquiring 9.6 million shares at a price of 8.76 RMB per share, totaling 84.096 million RMB [6][8]. - Following the equity change, Wang Ke's direct shareholding rose to 73,009,600 shares, representing 5.70% of the total share capital, while the combined voting rights of Wang Ke and his concerted actor, Wang Yaofang, increased to 25.66% [7][8]. Group 2: Information Disclosure Obligors - Wang Ke and his concerted actor, Wang Yaofang, are both natural persons, with Wang Ke serving as the General Manager of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. since September 2014 [2][3]. - Wang Yaofang, also a concerted actor, has been involved in the same company since April 2003, indicating a strong familial and operational connection between the two [4][5]. Group 3: Future Plans - Wang Ke plans to continue increasing his shareholding in the company within the next 12 months, estimating an additional purchase of approximately 12.4 million shares, depending on market conditions [6][7]. - There are currently no plans for significant changes to the company's main business operations, asset sales, mergers, or adjustments to the board of directors within the next year [10][11]. Group 4: Company Independence and Competition - The equity change will not affect the company's independence, as it will maintain its independent legal status and operational capabilities [12]. - There will be no new competition arising from this equity change, as the controlling shareholder and actual controller remain unchanged [12]. Group 5: Financial Transactions - The funds for the equity increase were sourced from Wang Ke's own and self-raised funds, with no involvement of related party transactions or asset swaps with the company [8][9]. - There have been no significant transactions between the information disclosure obligors and the company exceeding 30 million RMB in the past 24 months [12][13].